Mediastinum leiomyosarcoma

Summary

Mediastinum leiomyosarcoma (MONDO:0003376) is a disease. A subtype of mediastinum sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mediastinum leiomyosarcoma
Mondo ID	MONDO:0003376
DOID	DOID:5292
NCIT	C6619
UMLS	C1334660
MedGen	235310
GARD	0023488
Anatomy (UBERON)	UBERON:0003728
Is cancer (heuristic)	no

Also known as: leiomyosarcoma of mediastinum · leiomyosarcoma of the mediastinum · mediastinal leiomyosarcoma · mediastinum leiomyosarcoma

Data availability: 1 cell line.

Disease family

This is a subtype of mediastinum sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › soft tissue sarcoma › mediastinum sarcoma › mediastinum leiomyosarcoma

Related subtypes (6): mediastinum rhabdomyosarcoma, mediastinum angiosarcoma, mediastinum synovial sarcoma, mediastinum liposarcoma, mediastinal extraskeletal osteosarcoma, malignant melanocytic peripheral nerve sheath tumor of mediastinum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.